Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

3
Is a Surprise Coming for Brown & Brown (BRO) This Earnings Season?

2018-07-19 zacks
Investors are always looking for stocks that are poised to beat at earnings season and Brown & Brown, Inc. (BRO - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
NBRV EIGR BRO NCS

3
Should You Buy Sierra (BSRR) Ahead of Earnings?

2018-07-19 zacks
Investors are always looking for stocks that are poised to beat at earnings season and Sierra Bancorp (BSRR - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report. That is because Sierra is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for BSRR in this report.
BSRR NBRV EIGR NCS

3
Is a Surprise Coming for 1st Constitution Bancorp (FCCY) This Earnings Season?

2018-07-19 zacks
Investors are always looking for stocks that are poised to beat at earnings season and 1st Constitution Bancorp (FCCY - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report. That is because 1st Constitution Bancorp is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to earnings beat.
NBRV EIGR FCCY NCS

6
Berkshire Hathaway (BRK-B) Soars: Stock Adds 5.3% in Session

2018-07-19 zacks
Berkshire Hathaway Inc. (BRK.B - Free Report) was a big mover last session, as the company saw its shares rise more than 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $184.91 to $192.00 in the past one-month time frame.
BRK.A HALL NBRV EIGR NCS

3
CSX Corporation (CSX) Catches Eye: Stock Jumps 7.1%

2018-07-19 zacks
CSX Corporation (CSX - Free Report) was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $63.59 to $66.50 in the past one-month time frame. The move came after the company reported solid second-quarter 2018 results.
GWR NBRV EIGR CSX NCS

3
United Continental (UAL) in Focus: Stock Moves 8.8% Higher

2018-07-19 zacks
United Continental Holdings, Inc. (UAL - Free Report) was a big mover last session, as the company saw its shares rise nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $68.88 to $74.42 in the past one-month time frame.
NBRV EIGR UAL ATSG NCS

3
PPG Industries (PPG) Q2 Earnings, Sales Beat Estimates

2018-07-19 zacks
PPG Industries, Inc. (PPG - Free Report) , based in Pennsylvania, has a diversified business and a leading position in several paints and coatings end markets. Earnings PPG Industries’ adjusted earnings were $1.90 per share for the second quarter, up around 6% year over year. It beat the Zacks Consensus Estimate of $1.89. Revenues PPG Industries posted revenues of $4,131 million, up roughly 9% year over year.
PPG NBRV EIGR NCS

3
MGIC Investment (MTG) Soars: Stock Adds 9.1% in Session

2018-07-19 zacks
MGIC Investment Corporation (MTG - Free Report) was a big mover last session, as the company saw its shares rise more than 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. The stock picked up sharply from the near-flat trend of $10.71 to $11.37 in the past one month time frame.
NBRV EIGR LGGNY MTG NCS

3
Why Cleveland-Cliffs (CLF) Might Surprise This Earnings Season

2018-07-19 zacks
Investors are always looking for stocks that are poised to beat at earnings season and Cleveland-Cliffs Inc. (CLF - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report. That is because Cleveland-Cliffs is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to earnings beat.
NBRV EIGR NCS

3
Is a Surprise Coming for Halliburton (HAL) This Earnings Season?

2018-07-19 zacks
Investors are always looking for stocks that are poised to beat at earnings season and Halliburton Company (HAL - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
NBRV EIGR NCS

3
Alliance Data (ADS) Q2 Earnings and Revenues Beat Estimates

2018-07-19 zacks
Have you been eager to see how Alliance Data Systems Corporation (ADS - Free Report) performed in the second quarter in comparison with the market expectations? Let’s quickly scan through the key facts from this OH-based property and casualty insurer’s earnings release this morning. An Earnings Beat Alliance Data reported adjusted earnings per share of $5.01 per share, beating the Zacks Consensus Estimate of $4.
NBRV EIGR ADS NCS

3
Should You Sell Bank of Hawaii (BOH) Before Earnings?

2018-07-19 zacks
Investors are always looking for stocks that are poised to beat at earnings season and Bank of Hawaii Corporation (BOH - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
NBRV BOH EIGR NCS

3
Should You Buy Heartland Financial USA (HTLF) Ahead of Earnings?

2018-07-19 zacks
Investors are always looking for stocks that are poised to beat at earnings season and Heartland Financial USA, Inc. (HTLF - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
HTLF NBRV EIGR NCS

3
Should You Buy TD Ameritrade (AMTD) Ahead of Earnings?

2018-07-19 zacks
Investors are always looking for stocks that are poised to beat at earnings season and TD Ameritrade Holding Corporation (AMTD - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
NBRV AMTD EIGR NCS

3
Blackstone (BX) Beats on Q2 Earnings & Revenue Estimates

2018-07-19 zacks
Have you been eager to see how The Blackstone Group L.P. (BX - Free Report) performed in Q2 in comparison with the market expectations? Let’s quickly scan through the key facts from this New York-based premier global investment and advisory firm’s earnings release this morning: An Earnings Beat Blackstone came out with economic net income of 90 cents per share, which beat the Zacks Consensus Estimate of 71 cents.
NBRV EIGR NCS

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 62957M104